<DOC>
	<DOCNO>NCT00278161</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy , cyclophosphamide , work different way stop growth cancer cell , either kill cell stop divide . Colony-stimulating factor , pegfilgrastim , may increase number immune cell find bone marrow peripheral blood may help immune system recover side effect chemotherapy . Giving rituximab cyclophosphamide together pegfilgrastim may effective treat leukemia non-Hodgkin 's lymphoma . PURPOSE : This phase II trial study well give rituximab cyclophosphamide together pegfilgrastim work treat patient B-cell leukemia , low-grade non-Hodgkin 's lymphoma , mantle cell lymphoma .</brief_summary>
	<brief_title>Rituximab , Cyclophosphamide , Pegfilgrastim Treating Patients With Leukemia Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety high-dose cyclophosphamide , rituximab , pegfilgrastim patient B-cell leukemia low-grade mantle cell lymphoma . - Determine molecular response rate patient treat regimen . OUTLINE : This open-label study . Patients receive rituximab IV 30-60 minute day 1 , 4 , 8,11 , 45 , 52 , cyclophosphamide IV 1 hour day 15-18 , pegfilgrastim subcutaneously day 19 20 absence unacceptable toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 32 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow Bcell leukemias lymphoma , define World Health Organization criterion : Chronic lymphocytic leukemia/small lymphocytic lymphoma Bcell prolymphocytic leukemia Lymphoplasmacytic leukemia Marginal zone lymphoma ( splenic , extranodal , nodal ) Follicular lymphoma ( grade 1 2 ) Mantle cell lymphoma No minimal ( approximately 10 % ) morphologically identifiable cancer cell bone marrow biopsy When cancer cell morphologically difficult distinguish normal cell , flow cytometry must show 10 % identifiable cancer cell Must receive ≤ 12 month prior cytotoxic therapy , achieve least partial response NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : ECOG performance status 01 WBC ≥ 3,000/mm^3 Hemoglobin ≥ 10.0 g/dL Platelet count ≥ 75,000/mm^3 Serum creatinine ≤ 2.0 mg/dL Total bilirubin ≤ 2 mg/dL unless secondary tumor AST ALT &lt; 2 time upper limit normal Normal ( ≥ 45 % ) leave ventricular cardiac ejection fraction ( determine echocardiogram MUGA scan ) DLCO &gt; 50 % predict Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known sensitivity E. coliderived product ( e.g . filgrastim [ GCSF ] , insulin , asparaginase , growth hormone , recombinant interferon alfa2b ) treatment study drug No active infection require oral intravenous antibiotic No second malignancy basal cell squamous cell carcinoma skin situ carcinoma cervix unless malignancy localize treat resect &gt; 90 % probability cure PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior antiCD20 therapy allow provided patient achieve partial complete response No concurrent steroid rituximab administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>small lymphocytic lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
</DOC>